Dr Steve Projan | Senior Vice President of Innovative Medicines, Research and Development and Head of Infectious Diseases and Vaccines
MedImmune Inc | United States

Dr Steve Projan, Senior Vice President of Innovative Medicines, Research and Development and Head of Infectious Diseases and Vaccines, MedImmune Inc

Dr. Steve Projan is the Head of Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune, leading a cross-functional team dedicated to the therapeutic area strategy, prioritization and advancement of the company’s infectious disease and vaccine portfolio. Dr. Projan joined MedImmune in 2010 as senior vice president of research and development and head of the Infectious Diseases & Vaccines iMED. Prior to joining MedImmune, Dr. Projan served as vice president and global head of Infectious Diseases at Novartis. He previously spent 15 years at Wyeth in roles of increasing responsibility with his last post as vice president and head of Biological Technologies. During his time at Wyeth, Dr. Projan started the Biologics Discovery Group (covering all therapeutic areas) and initiated multiple collaborations and partnerships, most notably with Cambridge Antibody Technology (now a part of MedImmune/AZ).  Prior to Dr. Projan’s work in the industry, he spent 14 years at the Public Health Research Institute and presently has over 110 publications to his credit.  Dr. Projan received a bachelor of science from the Massachusetts Institute of Technology and masters of arts and philosophy in biological sciences and a doctorate in molecular genetics from Columbia University.

Appearances:



DC Pre-congress WS day April 2 @ 09:00

Incorporating passive immunization with active immunization – The role and use mABs for infectious diseases

Should there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically? Join this workshop to understand how these treatments are increasingly combined and the role of both passive and active immunization in future.

An overview of the scientific rationale & landscape survey of antibodies in preclinical and clinical development for infectious diseases

RSV and bacterial (Sa and Pa) prophylactic monoclonals in development

Current Sa antibodies used effectively for prophylaxis

True Human™ antibody therapy against C. difficile
 

back to speakers